Qinlock
What Qinlock is used for
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Qinlock
- Active substance
- ripretinib
- Disease area
- Gastrointestinal Stromal Tumors
- Medicine group
- Antineoplastic agents
- ATC code
- L01
- Marketing authorisation holder
- Deciphera Pharmaceuticals (Netherlands) B.V.
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Qinlock
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Qinlock used for?
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
What is the active substance in Qinlock?
Qinlock contains ripretinib.
Who makes Qinlock?
The EU marketing authorisation holder is Deciphera Pharmaceuticals (Netherlands) B.V..
Is Qinlock an orphan medicine?
Yes. Qinlock is designated an orphan medicine in the EU, for a rare disease (Gastrointestinal Stromal Tumors).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU